Contrasting CareRx (OTCMKTS:CHHHF) and Exagen (NASDAQ:XGN)

Exagen (NASDAQ:XGN) and CareRx (OTCMKTS:CHHHF) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

75.2% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Exagen and CareRx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57 million	2.69	-$19.95 million	($0.81)	-9.12
CareRx	N/A	N/A	N/A	N/A	N/A

CareRx has lower revenue, but higher earnings than Exagen.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Exagen and CareRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1	0	7	1	2.89
CareRx	0	0	0	0	0.00

Exagen currently has a consensus price target of $9.62, suggesting a potential upside of 30.24%. Given Exagen’s stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than CareRx.

Profitability

This table compares Exagen and CareRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
CareRx	N/A	N/A	N/A

Summary

Exagen beats CareRx on 7 of the 10 factors compared between the two stocks.

About Exagen

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

About CareRx

CareRx Corporation, together with its subsidiaries, provides pharmacy services to seniors homes and other congregate care settings in Canada. The company offers medication management, technology, and program solutions. It serves long-term care homes, retirement homes, assisted living facilities, and group homes. The company was formerly known as Centric Health Corporation and changed its name to CareRx Corporation in June 2020. CareRx Corporation was incorporated in 2001 and is based in Toronto, Canada.